Healthcare / BiotechnologyNasdaqCM
$3.55
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-4.7M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$43M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-123.2%
↓Gross Margin
27.8%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2026 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-252.4%
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.0M · net income $-8.2M · FCF $-5.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $2.0M | $2.0M | $2.1M | $2.1M | $2.1M | $1.4M | $943702.00 | $370647.00 | $245285.00 | — | — | — |
| Net Income | $-8.2M | $-8.2M | $-10.5M | $-5.5M | $-4.5M | $-6.2M | $-2.9M | $-2.7M | $-3.3M | $-2.7M | $-151260.00 | — |
| EBITDA | $-8.0M | $-8.0M | $-10.2M | $-5.1M | $-4.1M | $-5.8M | $-2.4M | $-1.9M | $-3.3M | — | — | — |
| EPS | -2.58 | -2.58 | -0.99 | -0.69 | -0.53 | -0.80 | -0.44 | — | — | — | — | — |
| Gross Margin | 27.8% | 27.8% | 34.7% | 41.3% | 36.1% | 39.0% | 33.5% | — | — | — | — | — |
| Operating Margin | -408.4% | -408.4% | -312.7% | -233.6% | -199.5% | -429.7% | -275.1% | -531.4% | -1358.1% | — | — | — |
| Net Margin | -404.1% | -404.1% | -489.9% | -263.0% | -215.6% | -434.3% | -310.8% | -734.3% | -1358.1% | — | — | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.04 | 0.02 | — | — | — | — | 0.01 | 0.07 | -0.06 |
| Current Ratio | 6.36 | 6.36 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-5.1M | $-5.1M | $-4.7M | $-3.6M | $-3.1M | $-2.9M | — | — | $-1.1M | — | — | — |
| Returns | ||||||||||||
| ROE | -123.2% | -123.2% | -163.1% | -85.2% | -52.3% | -52.1% | -41.2% | -1551.4% | -138.5% | -2199.0% | -654.6% | — |
| Valuation | ||||||||||||
| P/B | 6.19 | 6.19 | 12.89 | 3.45 | 4.89 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | -4.8% | -4.8% | 2.6% | 0.3% | — | 50.7% | 154.6% | 51.1% | — | — | — | — |
| EPS Growth | -160.6% | -160.6% | -43.5% | -30.2% | — | -82.9% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.99 → -2.58
Residual
-56.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.